Savara (NASDAQ:SVRA) Shares Down 6.6% – Time to Sell?

Savara Inc (NASDAQ:SVRA)’s share price fell 6.6% during trading on Thursday . The stock traded as low as $3.24 and last traded at $3.26. 746,943 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 1,267,962 shares. The stock had previously closed at $3.49.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SVRA. HC Wainwright reduced their price target on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Evercore ISI reiterated an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Savara in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Price Performance

The business’s 50-day simple moving average is $3.52 and its two-hundred day simple moving average is $4.02. The firm has a market cap of $550.90 million, a price-to-earnings ratio of -7.47 and a beta of 0.92. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). As a group, research analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Insider Buying and Selling at Savara

In other news, Director Joseph S. Mccracken bought 20,000 shares of the stock in a transaction dated Tuesday, November 19th. The shares were bought at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 5.13% of the company’s stock.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP lifted its holdings in shares of Savara by 24.7% in the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after purchasing an additional 1,600,000 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its stake in Savara by 103.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after acquiring an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC boosted its holdings in Savara by 198.2% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Savara by 54.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company’s stock worth $2,928,000 after acquiring an additional 242,249 shares during the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in shares of Savara by 34.5% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,546,850 shares of the company’s stock worth $6,234,000 after acquiring an additional 396,850 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.